HOWARD BAILEY was named director of the University of Wisconsin Carbone Cancer Center, effective April 1. Bailey has served as interim director since September 2013.
FDA approved Zarxio, making Sandoz's granulocyte-colony stimulating factor the first biosimilar product to enter the U.S. market.
After months of training, hundreds of hours spent in a high-altitude sleep tent, and almost a week spent ascending the mountain, our climbing group was destined to have only 12 minutes at Mt. Kilimanjaro's summit. However, that was enough to pay tribute to the 200,000 heroes who have participated in more than a half-century of SWOG cancer clinical trials.
Citing a dramatic improvement in overall survival in second-line squamous non-small cell lung cancer, FDA rapidly approved the Bristol-Myers Squibb drug Opdivo (nivolumab).
FDA granted accelerated approval to Farydak (panobinostat) for the treatment of multiple myeloma. The FDA had previously granted Farydak priority review and an orphan product designation.
BEAUMONT HOSPITAL'S Cancer Institute in Royal Oak, Mich., has begun construction of a proton therapy center. This will be the first single-room proton treatment center of its kind in Michigan.
PATRICK HWU was named division head of Cancer Medicine at MD Anderson Cancer Center, effective March 4. Hwu joined MD Anderson in 2003 as the first chair of Melanoma Medical Oncology. He is also currently chair of Sarcoma Medical Oncology.
The FDA issued a safety alert regarding the design of endoscopic retrograde cholangiopancreatography duodenoscopes, and how it may impede effective cleaning of the reusable device.
Bristol-Myers Squibb Company and Rigel Pharmaceuticals Inc. entered into a collaboration for the discovery, development and commercialization of cancer immunotherapies based on Rigel's portfolio of small molecule TGF beta receptor kinase inhibitors.
FDA granted Rintega (rindopepimut) a Breakthrough Therapy Designation for the treatment of adult patients with EGFRvIII-positive glioblastoma.
